Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)
Launched by CHANGHAI HOSPITAL · Aug 7, 2008
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
ERCP is an important endoscopic technique in the diagnosis and treatment of pancreatic and biliary diseases. Duodenal peristalsis can make cannulation of the papilla and the necessary therapeutic procedures difficult. Intravenous hyoscine-N-butylbromide is often used during ERCP to inhibit duodenal motility and enhance cannulation in China. However, the pharmaceutical agent is occasionally associated with serious complications such as cardiovascular events or anaphylactic shock. Hyoscine-N-butylbromide may also affect the ocular, urinary, and salivary systems.
Drotaverine hydrochloride is ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients undergoing ERCP above the age of 18 years
- Exclusion Criteria:
- • Patient with Billroth II gastrectomy
- • Known previous sphincterotomy
- • Active acute pancreatitis before ERCP
- • Ongoing acute cholangitis before ERCP
- • Hypotension (systolic blood pressure \< 100 mmHg)
- • Second-degree and third-degree atrioventricular block
- • Heart failure
- • Glaucoma
- • Obstructive uropathy
- • Impaired renal function (serum creatinine \> 133μmol/L)
- • Pregnant or breastfeeding women
About Changhai Hospital
Changhai Hospital is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence, the hospital integrates cutting-edge medical technologies and a multidisciplinary approach to patient care. Changhai Hospital actively collaborates with research organizations and healthcare professionals to conduct rigorous clinical trials aimed at developing new treatments and improving patient outcomes. By prioritizing patient safety and ethical standards, the hospital plays a pivotal role in contributing to the advancement of medical knowledge and the enhancement of therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, , China
Hangzhou, , China
Harbin, , China
Shanghai, , China
Patients applied
Trial Officials
Zhaoshen Li, MD
Principal Investigator
Changhai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials